藥明康德(603259.SH)：認繳120 Capital的1588.0899萬美元份額
格隆匯 4 月 2日丨藥明康德(603259.SH)公佈，北京時間2021年4月2日，公司全資子企業WuXi PharmaTech Healthcare Fund I L.P.(“WuXi Fund I”)與120 Capital GP, L.P.(“普通合夥人”)簽署Subscription Agreement(“認購協議”)，約定由WuXi Fund I認繳120 Capital, L.P. (“投資基金”或“120 Capital”)的1588.0899萬美元份額，約佔已募集投資基金份額的10%。
截至公吿日，WuXi Fund I尚未支付投資款，後續WuXi Fund I將以自有資金根據合夥協議的要求履行投資款的支付義務。
基金規模：投資基金預計募集總額為5億美元，WuXi Fund I此次認繳1588.0899萬美元后，投資基金已募集158,808,989美元資金。
投資基金為一家依據美國特拉華州法律成立的有限合夥企業，主要專注於投資位於中國(包含中國大陸、中國香港特別行政區、中國台灣)、北美和歐洲地區的醫療健康和生命科學企業。
120 Capital的投資將主要針對中國(包含中國大陸、中國香港特別行政區、中國台灣)、北美和歐洲地區的醫療健康和生命科學企業。投資基金的管理團隊擁有在中美兩地豐富的創業、投資經驗和廣泛的行業資源，能夠發掘該領域高質量的創新成果，並通過投資幫助此類企業獲得資金以加速其創新成果轉化。公司以較低比例投資120 Capital作為其有限合夥人，一方面有望使公司在投資風險可控的前提下，獲得風險投資相關的財務收益；另一方面，120 Capital投資所針對的早期生物科技企業是本公司重要的潛在客户羣體，有助於本公司進一步拓展中國及海外市場，擴展本公司的主營業務。公司在保證日常經營發展所需資金的前提下，以自有資金參與認繳投資基金份額，此次投資不會對公司財務狀況和經營成果產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
